C-Type Natriuretic Peptides and Methods Thereof in Treating Acute Lung Injury
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 28, 2023
app pub date -
Jun 11, 2021
filing date -
Jun 11, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present disclosure relates to the treatment of lung, liver, and/or kidney injury, by administering to a subject in need thereof a therapeutically effective amount of a (very) long acting C-type natriuretic peptide (CNP), CNP derivative, (very) long acting CNP derivative, or (very) long acting CNP receptor (NPRB) agonist. The disclosure also relates to the treatment of non-cardiovascular causes of low blood oxygenation, elevated levels of inflammatory cells in the lung, pulmonary edema, sepsis, bacteremia, fibrosis in general, and/or interstitial lung disease using the same.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully